Calidi Biotherapeutics to Detail RedTail Platform Progress in Investor Webinar
Event summary
- Calidi Biotherapeutics to host investor webinar on June 9, 2026, at 1:15 PM PT.
- CEO Eric Poma, Ph.D., to present updates on RedTail platform and CLD-401 candidate.
- Company targeting IND submission for CLD-401 by year-end 2026.
- Recent preclinical data highlights tumor-selective viral replication and immune evasion.
- Webinar to include Q&A session and discussion of upcoming milestones.
The big picture
Calidi Biotherapeutics is positioning itself as a leader in targeted genetic medicines with its RedTail platform, which aims to overcome systemic delivery challenges in oncology. The upcoming webinar highlights the company's push toward clinical milestones amid a competitive landscape of next-generation virotherapies. Success in advancing CLD-401 could validate the platform's broader potential across multiple disease areas.
What we're watching
- Clinical Timeline
- Whether Calidi can meet its year-end 2026 IND submission target for CLD-401.
- Platform Potential
- How the RedTail platform's systemic delivery capabilities will position it against competitors in targeted virotherapy.
- Data Validation
- The pace at which preclinical data translates into clinical efficacy for Calidi's lead candidate.
Related topics